

Federico Piacentini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1901898/publications.pdf>

Version: 2024-02-01

57
papers

1,748
citations

430874

18
h-index

276875

41
g-index

58
all docs

58
docs citations

58
times ranked

2729
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Carcinoid Crisis: A Misunderstood and Unrecognized Oncological Emergency. <i>Cancers</i> , 2022, 14, 662. | 3.7 | 7 |
| 2 | Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist. <i>Clinical Breast Cancer</i> , 2022, 22, 289-299. | 2.4 | 3 |
| 3 | Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7079. | 4.1 | 4 |
| 4 | Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience. <i>Future Oncology</i> , 2022, 18, 2651-2659. | 2.4 | 0 |
| 5 | Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 12. | 5.2 | 9 |
| 6 | The Role of Exosomes in Breast Cancer Diagnosis. <i>Biomedicines</i> , 2021, 9, 312. | 3.2 | 20 |
| 7 | The Prognostic Role of Early Skeletal Muscle Mass Depletion in Multimodality Management of Patients with Advanced Gastric Cancer Treated with First Line Chemotherapy: A Pilot Experience from Modena Cancer Center. <i>Journal of Clinical Medicine</i> , 2021, 10, 1705. | 2.4 | 6 |
| 8 | Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. <i>European Journal of Cancer</i> , 2021, 153, 133-141. | 2.8 | 20 |
| 9 | Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature. <i>Cancers</i> , 2021, 13, 4894. | 3.7 | 6 |
| 10 | The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. <i>Pharmaceuticals</i> , 2021, 14, 43. | 3.8 | 8 |
| 11 | A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464. | 10.7 | 52 |
| 12 | <i>PIK3CA</i> Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 5843-5851. | 7.0 | 17 |
| 13 | <i>Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy</i> . <i>Cancer Management and Research</i> , 2019, Volume 11, 9563-9569. | 1.9 | 17 |
| 14 | Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. <i>Breast Cancer</i> , 2019, 26, 520-523. | 2.9 | 6 |
| 15 | Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. <i>BioMed Research International</i> , 2018, 2018, 1-8. | 1.9 | 9 |
| 16 | Immune characterization of breast cancer metastases: prognostic implications. <i>Breast Cancer Research</i> , 2018, 20, 62. | 5.0 | 54 |
| 17 | Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. <i>Cancer Management and Research</i> , 2018, Volume 10, 91-103. | 1.9 | 53 |
| 18 | Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications. <i>Oncotarget</i> , 2018, 9, 31606-31619. | 1.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2+ breast cancer: results from two prospective trials. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 295-302. | 2.5 | 17 |
| 20 | Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 85. | 4.1 | 25 |
| 21 | Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. <i>American Journal of Case Reports</i> , 2017, 18, 208-211. | 0.8 | 11 |
| 22 | Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. <i>Annals of Oncology</i> , 2016, 27, iv73. | 1.2 | 0 |
| 23 | Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. <i>Annals of Oncology</i> , 2016, 27, iv75. | 1.2 | 0 |
| 24 | Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. <i>Pharmacogenomics Journal</i> , 2016, 16, 472-477. | 2.0 | 22 |
| 25 | Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. <i>Annals of Oncology</i> , 2016, 27, iv69. | 1.2 | 1 |
| 26 | Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. <i>Annals of Oncology</i> , 2016, 27, 1867-1873. | 1.2 | 109 |
| 27 | Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. <i>Annals of Oncology</i> , 2016, 27, vi84. | 1.2 | 0 |
| 28 | Prognostic Factors for Breast Cancer: an Immunomorphological Update. <i>Pathology and Oncology Research</i> , 2016, 22, 449-452. | 1.9 | 17 |
| 29 | Abstract P2-08-03: Survival analysis of the prospective randomized Cher-Lob study: Correlation with tumor infiltrating lymphocytes. , 2016, , . | | 2 |
| 30 | Tumor Stroma Manipulation By MSC. <i>Current Drug Targets</i> , 2016, 17, 1111-1126. | 2.1 | 11 |
| 31 | Preoperative Carboplatin+Paclitaxel+Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study. <i>Annals of Surgical Oncology</i> , 2015, 22, 2881-2887. | 1.5 | 14 |
| 32 | Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1700-1710. | 10.7 | 108 |
| 33 | Abstract PD1-1: Tumor infiltrating lymphocytes and correlation with outcome in the Cher-LOB study. , 2015, , . | | 6 |
| 34 | Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of Letrozole-Lapatinib in Postmenopausal Hormone Receptor+Positive, Human Epidermal Growth Factor Receptor 2+Negative, Operable Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1050-1057. | 1.6 | 46 |
| 35 | Quantitative expression of estrogen receptor on relapse biopsy for ER-positive breast cancer: prognostic impact. <i>Anticancer Research</i> , 2014, 34, 3657-62. | 1.1 | 8 |
| 36 | Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. <i>Annals of Oncology</i> , 2013, 24, 2990-2994. | 1.2 | 96 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-Institution analysis. <i>Annals of Oncology</i> , 2013, 24, 101-108. | 1.2 | 145 |
| 38 | Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1989-1995. | 1.6 | 330 |
| 39 | Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. <i>Journal of Clinical Pathology</i> , 2012, 65, 503-506. | 2.0 | 13 |
| 40 | Primary pulmonary cancer colliding with metastatic breast carcinoma: Hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications. <i>Lung Cancer</i> , 2011, 74, 145-148. | 2.0 | 10 |
| 41 | Change in triple-receptor status between primary and recurrent breast cancer: prognostic impact. <i>Breast</i> , 2011, 20, S23. | 2.2 | 0 |
| 42 | Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer. <i>Annals of Surgical Oncology</i> , 2011, 18, 2150-2157. | 1.5 | 16 |
| 43 | Timing for starting second-line therapy in recurrent ovarian cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 49-55. | 2.4 | 11 |
| 44 | P1-12-18: Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts.. , 2011, , . | | 0 |
| 45 | Achievements and unmet needs in the management of advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2010, 117, 152-158. | 1.4 | 78 |
| 46 | Predictive and Prognostic Role of P53 According to Tumor Phenotype in Breast Cancer Patients Treated with Preoperative Chemotherapy: A Single-Institution Analysis. <i>International Journal of Biological Markers</i> , 2010, 25, 104-111. | 1.8 | 9 |
| 47 | Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, S62-S66. | 7.7 | 49 |
| 48 | Abstract P3-10-30: Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy. , 2010, , . | | 0 |
| 49 | Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis. <i>International Journal of Biological Markers</i> , 2010, 25, 104-11. | 1.8 | 7 |
| 50 | A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. <i>Annals of Oncology</i> , 2009, 20, 1193-1198. | 1.2 | 70 |
| 51 | Phase II, randomized trial of preoperative epirubicin-paclitaxel+/-Âgefitinib with biomarker evaluation in operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 110, 127-134. | 2.5 | 19 |
| 52 | Preoperative Chemotherapy plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer (CHERLOB Trial). <i>Clinical Breast Cancer</i> , 2008, 8, 192-194. | 2.4 | 29 |
| 53 | Letrozole Versus Letrozole plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized, Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB). <i>Clinical Breast Cancer</i> , 2008, 8, 97-100. | 2.4 | 15 |
| 54 | Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Asynchronous Paired Metastases: Impact on Patient Management. <i>Oncologist</i> , 2008, 13, 838-844. | 3.7 | 133 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor. <i>Haematologica</i> , 2008, 93, 1252-1255. | 3.5 | 19 |
| 56 | Progress in the Treatment of Early and Advanced Breast Cancer. , 2008, , 239-256. | | 0 |
| 57 | Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer. <i>Breast Cancer Research</i> , 2007, 9, . | 5.0 | 0 |